[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652655":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":29,"centralContacts":33,"locations":42,"responsibleParty":59,"collaborators":61,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":37,"eligibilityCriteria":70,"healthyVolunteers":67,"sex":71,"minAge":72,"maxAge":37,"enrollmentInfo":73,"targetDuration":37,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":87,"overallStatus":94,"whyStopped":37,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"University of Minnesota","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Mobile Cardiac Telemetry and Wearable Cardiac Monitor With Usual Care","EXPERIMENTAL","Participants with cancer will receive usual care plus mobile cardiac telemetry using the BodyGuardian Mini Plus ambulatory ECG monitor and a wearable cardiac monitor patch to collect heart sounds. Devices will be worn during cancer treatment to collect arrhythmia and cardiac function monitoring data.",[13,14],"Device: Mobile Cardiac Telemetry","Device: Wearable Cardiac Monitor",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DEVICE","Mobile Cardiac Telemetry","Participants will wear the FDA-cleared BodyGuardian Mini Plus mobile cardiac telemetry patch device for continuous ECG monitoring. The device will collect near-real-time heart rhythm data to identify arrhythmias during and following cancer treatment.",[9],[22],"BodyGuardian Mini Plus",{"type":17,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"Wearable Cardiac Monitor","Participants will wear an investigational non-significant risk wearable cardiac monitor patch that records heart sounds using an accelerometer. Data from the device will be used for offline analyses and will not be used for clinical decision-making in this study.",[9],[28],"WCM",[30],{"name":31,"affiliation":5,"role":32},"Suma Konety, MD","PRINCIPAL_INVESTIGATOR",[34,39],{"name":31,"role":35,"phone":36,"phoneExt":37,"email":38},"CONTACT","612-625-4465",null,"shkonety@umn.edu",{"name":40,"role":35,"phone":36,"phoneExt":37,"email":41},"Samantha Wansing","hoppx054@umn.edu",[43],{"facility":44,"status":37,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"M Health Fairview Clinics and Surgery Center","Minneapolis","Minnesota","55455","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-93.26384,44.97997,{"lat":54,"lon":53},[57,58],{"name":40,"role":35,"phone":36,"phoneExt":37,"email":41},{"name":31,"role":32,"phone":37,"phoneExt":37,"email":37},{"type":60,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR",[62],{"name":63,"class":64},"Boston Scientific Corporation","INDUSTRY","100652655","monitoring-for-cardiotoxicity-using-wearable-devices-while-undergoing-cancer-treatments-mct-wave-100652655",false,"NCT07776964","Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)","Inclusion Criteria:\n\n* Diagnosis of breast cancer, hematologic malignancy including leukemia or lymphoma, or multiple myeloma\n* At least 18 years of age\n* Capable of understanding and willing to sign a consent form for this study\n\nExclusion Criteria:\n\n* Known allergy to adhesive patches used for ambulatory EKG monitoring\n* Children\n* Cognitively challenged individuals\n* Prisoners\n* Active service military personnel","ALL","18 Years",{"count":74,"type":75},72,"ESTIMATED","INTERVENTIONAL",[78],"NA","This pilot study will evaluate the validity and feasibility of ambulatory cardiac monitoring to identify markers of cardiotoxicity in adults undergoing cancer treatment.\n\nParticipants with breast cancer, hematologic malignancy, or multiple myeloma will receive usual care plus two wearable patch monitors: mobile cardiac telemetry using the BodyGuardian Mini Plus ambulatory ECG monitor and an investigational wearable cardiac monitor that records heart sounds. The study will assess arrhythmias detected by mobile cardiac telemetry and explore whether heart sounds are associated with echocardiographic findings and cardiac biomarkers.\n\nParticipants will wear the devices during cancer treatment, with monitoring periods at baseline and possible repeat monitoring at 6-month and 12-month study visits.",[81,82,83,84,85,86],"Cardiotoxicity","Cancer","Cardiac Arrhythmia","Left Ventricular Dysfunction","Breast Cancer","Multiple Myeloma",[88,89,90,91,92,93],"MCT-WAVE","Mobile cardiac telemetry","Wearable cardiac monitor","Cardio-oncology","Ventricular arrhythmia","Breast cancer","NOT_YET_RECRUITING","2026-08-17",{"date":97,"type":98},"2026-08-20","ACTUAL",{"date":100,"type":75},"2026-09-01",{"date":102,"type":75},"2028-09-01",{"name":5,"class":6},1]